Apyx Medical Corp. (APYX) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Apyx Medical Corporation Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Introduces Fiscal Year 2019 Outlook
March 13, 2019 4:05 PM EDTAdvanced Energy Sales increase 40% year-over-year in Q4 and increase 71% year-over-year in FY18
CLEARWATER, Fla.--(BUSINESS WIRE)-- Apyx Medical Corporation (NASDAQ: APYX) (the Company), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion® Cosmetic Technology brand in the cosmetic surgery market, today reported financial results for its fourth quarter and fiscal year ended December31, 2018.
Fiscal Year 2018 Financial Summary:
2018 total revenue from continuing operations of approximately $16.7 million, up 63% year-over-year. Advanced Energy revenue of $13.1... More